DNAPrint Genomics Valuation
DNAPrint Genomics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of DNAPrint Genomics from reviewing the firm fundamentals such as Shares Owned By Institutions of 0.18 %, profit margin of (2.36) %, and Gross Profit of 446.37 K as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that DNAPrint Genomics' price fluctuation is out of control at this time. Calculation of the real value of DNAPrint Genomics is based on 3 months time horizon. Increasing DNAPrint Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the DNAPrint stock is determined by what a typical buyer is willing to pay for full or partial control of DNAPrint Genomics. Since DNAPrint Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of DNAPrint Stock. However, DNAPrint Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0 | Real 6.0E-6 | Hype 1.0E-5 | Naive 1.0E-6 |
The real value of DNAPrint Stock, also known as its intrinsic value, is the underlying worth of DNAPrint Genomics Company, which is reflected in its stock price. It is based on DNAPrint Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of DNAPrint Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of DNAPrint Genomics helps investors to forecast how DNAPrint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of DNAPrint Genomics more accurately as focusing exclusively on DNAPrint Genomics' fundamentals will not take into account other important factors: DNAPrint Genomics Total Value Analysis
DNAPrint Genomics is currently forecasted to have valuation of 5.64 M with market capitalization of 386.76 K, debt of 240 K, and cash on hands of 134.35 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the DNAPrint Genomics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.64 M | 386.76 K | 240 K | 134.35 K |
DNAPrint Genomics Investor Information
The company had not issued any dividends in recent years. DNAPrint Genomics had 1:20 split on the 12th of July 2005. Based on the key indicators related to DNAPrint Genomics' liquidity, profitability, solvency, and operating efficiency, DNAPrint Genomics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.DNAPrint Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. DNAPrint Genomics has an asset utilization ratio of 23.69 percent. This implies that the Company is making $0.24 for each dollar of assets. An increasing asset utilization means that DNAPrint Genomics is more efficient with each dollar of assets it utilizes for everyday operations.DNAPrint Genomics Ownership Allocation
About 99.82 % of DNAPrint Genomics outstanding shares are held by general public with 0.18 (percent) by institutions.DNAPrint Genomics Profitability Analysis
The company reported the previous year's revenue of 2.43 M. Net Loss for the year was (12.35 M) with profit before overhead, payroll, taxes, and interest of 446.37 K.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates DNAPrint Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in DNAPrint Genomics and how it compares across the competition.
About DNAPrint Genomics Valuation
The stock valuation mechanism determines DNAPrint Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of DNAPrint Genomics. We calculate exposure to DNAPrint Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of DNAPrint Genomics's related companies.DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany. DNAPRINT GENOMICS is traded on OTC Exchange in the United States.
Complementary Tools for DNAPrint Stock analysis
When running DNAPrint Genomics' price analysis, check to measure DNAPrint Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DNAPrint Genomics is operating at the current time. Most of DNAPrint Genomics' value examination focuses on studying past and present price action to predict the probability of DNAPrint Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DNAPrint Genomics' price. Additionally, you may evaluate how the addition of DNAPrint Genomics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |